IL32 and COVID-19: In patients with available follow-up (n=96), IL-32 remained stable up to one-year post-discharge (+0.03 ± 0.12 log<sub>10</sub> pg/ml, p=0.970; 2.55 ± 0.15 hospital admission vs. follow-up 3-12 months 2.58 ± 0.15 log<sub>10</sub> pg/ml).<h4>Conclusions</h4>IL-32 levels increased following COVID-19, especially during the initial severe wave, and correlated with some markers of inflammation.